
Guggenheim raised the firm’s price target on BrightSpring Health (BTSG) to $84 from $81 and keeps a Buy rating on the shares after what the firm calls “another clean beat
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BTSG | BrightSpring Health Services, Inc. | 71.37 | 39.30 | 122.53% |
| Name | Price | % Change | |
|---|---|---|---|
| $71.37 | +122.53% |

Guggenheim raised the firm’s price target on BrightSpring Health (BTSG) to $84 from $81 and keeps a Buy rating on the shares after what the firm calls “another clean beat

Leerink raised the firm’s price target on BrightSpring Health (BTSG) to $92 from $72 and keeps an Outperform rating on the shares. The firm says Q3 results brought forth a

TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $84 from $81 and keeps a Buy rating on the shares. The firm updated its model following Q3

Wells Fargo raised the firm’s price target on BrightSpring Health (BTSG) to $82 from $78 and keeps an Overweight rating on the shares. The firm is raising estimates following strong

UBS raised the firm’s price target on BrightSpring Health (BTSG) to $92 from $85 and keeps a Buy rating on the shares. BrightSpring’s growth outlook remains positive, supported by a

In a report released on October 30, Erin Wright from Morgan Stanley maintained a Buy rating on BrightSpring Health Services, Inc., with a price target of $80.00. Erin Wright’s Buy

BrightSpring Health Services, Inc. (($BTSG)) has held its Q3 earnings call. Read on for the main highlights of the call. BrightSpring Health Services delivered a strongly positive earnings call, marked

Let’s look at 2 healthcare stocks with a perfect 10/10 TipRanks Smart Score, have a Strong Buy consensus from Wall Street analysts and have seen hedge funds or insiders buying

Reports Q3 revenue $4.21B, consensus $3.87B. “Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses,” said

FY26 consensus $15.37B. Raises FY26 adjusted EBITDA view to $850M-$860M from $820M-$845M. The Amedisys and LHC branches acquisition is expected to contribute approximately $35M in Adjusted EBITDA in 2026 Published
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Assigned | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Assigned | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 14, 2026 | ||||
| buy | Assigned | Aug 3, 2026 | ||||
| buy | Reiterated | Aug 3, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 26, 2027TBA | $14.17B | $0.55 | $4.35B | -0.04 | 43.42 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.